WITHDRAWN: A disintegrin and metalloprotease 8 (ADAM8) expression correlates with prognosis in solid tumors: A systematic review and meta-analysis

Abstract

// Qianna Jin 1 , Jiaqing Cao 2 , Nan He 3,4 , Xin Jin 4 , Tao Liu 4 , Xiaoming Lu 3,4 , Kaixiong Tao 3 and Guobin Wang 3 1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China 2 Department of Gastrointestinal Surgery, the Second Affiliated Hospital of Nanchang University, Nanchang 330006, China 3 Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong, University of Science and Technology, Wuhan, China 4 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China Correspondence to: Nan He, email: hero_nan@163.com Keywords : ADAM8; solid tumor; prognosis; survival; meta-analysis Received: March 01, 2017     Accepted: August 29, 2017     Epub: January 05, 2018 Abstract A disintegrin and metalloprotease 8 (ADAM8) expression appears to be predictive of prognosis in various solid tumors, though the evidence is not yet conclusive. We therefore performed a meta-analysis to explore the relationship between ADAM8 expression and prognosis in patients with solid tumors. Relevant publications were searched in several widely used databases, and 12 studies (1722 patients) were included in the meta-analysis. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the strength of the association between ADAM8 expression and prognosis. Associations between ADAM8 expression and prognosis were observed for 3-year overall survival (OR = 3.09, 95% CI = 2.33 to 4.10, P < 0.00001) and 5-year overall survival (OR = 4.15, 95% CI = 3.14 to 5.48, P < 0.00001). Similar results were observed when disease free survival (DFS) were analyzed, 3-year DFS (OR = 2.47, 95% CI = 1.66 to 3.69, P < 0.00001) and 5-year DFS (OR = 3.30, 95% CI = 2.29 to 4.74, P < 0.00001). In conclusion, elevated ADAM8 expression is associated with poor prognosis in most solid tumors. ADAM8 is a valuable biomarker for prognosis prediction and a promising therapeutic target in human solid tumors.